Shinpoong Pharmaceutical Rises 5.31% Amid Anthelmintic (Fenbendazole, etc.) Theme Uptrend
On the 22nd, the anthelmintic (including Fenbendazole) theme rose by 4.07% compared to the previous day, showing strong performance, while Shinpung Pharmaceutical, a related stock drawing attention, surged by 5.31% compared to the previous day. Shinpung Pharmaceutical is known as a pharmaceutical company focused on the sales of specialized therapeutic drugs.
[Graph] Price Fluctuations of Major Stocks in the Anthelmintic (including Fenbendazole) Theme

According to the analysis by Thinkpool Robo Algorithm RASSI, Shinpung Pharmaceutical ranked 3rd out of 7 stocks in the quant financial ranking by exceeding the theme's average scores in growth, stability, and profitability. This can be interpreted as Shinpung Pharmaceutical having a relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.
[Table] Top Stocks by Financial Scores within the Theme

※ The quant financial scores are the results of the Robo Algorithm's analysis based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.
※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
Hot Picks Today
"Suspicious Timing?"...Trump Traded Stocks After Praising Wartime Capabilities
- "Even If I Lose My Investment, the Government Will Cover It"... The Fund Attracting Retail Investors' Attention [Weekend Money]
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "I Went to 10 Convenience Stores and Still Couldn't Buy It": The Bread Sensation That Sold 100 Million Units Already [The Way We Shop Now]
- "Contact Me First If Houses Are Built": Wealthy Clients Eyeing... Will Ultra-High-End Residences Worth 20 Billion Won Be Developed? [Real Estate AtoZ]
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.